BiotechTube
Acrigen Biosciences

Acrigen Biosciences

Philadelphia, United States· Est.
acrigen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

Acrigen Biosciences is a private, pre-clinical stage biotech focused on overcoming the critical challenge of off-target editing in CRISPR-based therapeutics. The company's core technology platform combines two proprietary components: novel αCas and μCas nuclease libraries discovered through its AcrTAIN™ bioinformatics platform, and engineered ErAcr proteins designed to selectively inhibit off-target editing events. This approach is intended to create a tunable, high-precision gene editing toolbox for both in vivo and ex vivo applications. Acrigen appears to operate primarily as a platform technology company, seeking partnerships and licensing opportunities for its novel editors and precision-enhancing proteins.

Genetic Diseases

Technology Platform

Proprietary platform combining novel CRISPR-Cas nuclease libraries (αCas and μCas) discovered via the AcrTAIN™ bioinformatics engine with engineered anti-CRISPR proteins (ErAcrs). The ErAcrs are designed to selectively inhibit off-target editing, creating a high-precision, tunable gene editing system for in vivo and ex vivo therapeutics.

Funding History

1
Total raised:$5.5M
Seed$5.5M

Opportunities

The critical need for safer, more precise CRISPR systems creates a large market for Acrigen's technology, both for internal drug development and for out-licensing to larger biopharma companies.
Successfully demonstrating superior specificity could enable therapies for a broader range of genetic diseases, particularly those requiring editing in sensitive tissues.

Risk Factors

High technical risk in proving the selective inhibition of off-targets by ErAcr proteins works robustly in human therapeutic contexts.
Intense competition from other CRISPR editing companies developing alternative precision technologies.
Dependency on securing ongoing venture funding as a pre-revenue, early-stage platform company.

Competitive Landscape

Acrigen competes in the crowded CRISPR therapeutics space, facing established players like CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine, as well as newer entrants focused on precision editing such as Beam Therapeutics (base editing) and Prime Medicine (prime editing). Its differentiation lies in the unique combination of novel nucleases and engineered anti-CRISPR proteins for real-time control of specificity.

More companies in CRISPR / Gene Editing →More companies in United States →